Monoclonal Antibody-Directed Therapy

• Eará dahkkit: Kayser, Veysel (Doaimmaheaddji), Datta-Mannan, Amita (Doaimmaheaddji)
• Materiálatiipa: Elektrovnnalaš Girjji oassi
• Giella: eaŋgalasgiella
• Almmustuhtton: Basel MDPI - Multidisciplinary Digital Publishing Institute 2022
• Fáttát: Medicine; Pharmaceutical industries; therapeutic antibody; stability; aggregation; manufacture challenges; formulation; antibodies; site-specific conjugation; bioconjugates; ADC; antibody-drug conjugates; payloads; linkers; nucleic acids; ADME; developability; glycosylation; post-translational modifications; pharmacokinetics; effector functions; antibody-dependent cell-mediated cytotoxicity; complement-dependent cytotoxicity; immunogenicity; pharmacodynamics; glycoengineering; type III secretion system; prophylaxis; antibacterials; antibiotics; HIV/AIDS; co-formulation; high concentration; analytical characterization; antibody (s); T-cell engagers; bispecific antibodies; immunotherapy; oncology; antibody engineering; immunological synapse
• Liŋkkat: DOAB: download the publication; DOAB: description of the publication

Čoahkkáigeassu

The book deals with therapeutic monoclonal antibodies (mAbs) broadly, and relevant topics such as challenges and opportunities, next-generation antibody products, Antibody-Drug-Conjugates (ADC), bispecifics, glycosylation, and T-cell engagers are covered. Each topic has been written by leading groups around the world and the book should be of interest to researchers from both academia and industry.

Olgguldas hápmi

1 electronic resource (142 p.)

ISBN

books978-3-0365-2872-4
9783036528724
9783036528731

Beassan

Open Access